Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3SBio Files For Approval For Interleukin-2 NuLeusin

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced
Advertisement

Related Content

Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination
Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., E.U. Markets
Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., EU Markets
3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO
Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
3SBio Growth Driven By EPO With Shaky Future
3SBio Growth Driven By EPO With Shaky Future
Advertisement
UsernamePublicRestriction

Register

SC067221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel